Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3519

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3519). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3519 3)

Label for Duloxetine 60 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label states each capsule contains enteric-coated pellets equivalent to 60 mg Duloxetine. It includes packaging and lot details, barcodes, manufacturer information (Ajanta Pharma Limited, India), and warnings such as keeping out of reach of children and storage temperature instructions.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph showing the proportion of patients with relapse over time from randomization to relapse (in days). The graph compares two treatments: Placebo, represented by a dashed line, and Duloxetine, represented by a solid line. The y-axis displays the proportion of patients with relapse from 0 to 1, and the x-axis shows time up to 250 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The X-axis represents percent improvement in pain from baseline, and the Y-axis represents the percentage of patients improved. The graph shows Duloxetine with a consistently higher percentage of patient improvement across pain improvement levels compared to placebo.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph comparing the proportion of patients with relapse over time from randomization to relapse in days for Duloxetine versus placebo. The x-axis represents days from 0 to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The graph shows a lower relapse proportion for Duloxetine compared to placebo across the time period.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph illustrating the percentage of patients improved relative to percent improvement in pain from baseline, comparing Duloxetine at doses of 60 mg twice daily, 60 mg once daily, and 20 mg once daily, along with placebo. Four lines represent each group with patient improvement percentages plotted against pain improvement percentages.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It includes three data series: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The graph shows higher patient improvement percentages for Duloxetine groups across various levels of pain improvement compared to placebo.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph showing percent improvement in pain from baseline on the x-axis and the percentage of patients improved on the y-axis. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, indicating higher patient improvement percentages for the Duloxetine groups across most levels of pain improvement.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, with Duloxetine groups showing higher improvement percentages across most pain improvement thresholds.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The graph shows two lines with data points indicating patient improvement percentages across varying levels of pain improvement.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved between Duloxetine 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows a higher percentage of patient improvement across various pain improvement thresholds compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved at various percentages of pain improvement from baseline (BOCF) for Duloxetine 60 mg once daily versus placebo. The x-axis measures percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine is represented by a solid line with diamond markers, while placebo is shown with a dashed line and x markers.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure diagram of duloxetine hydrochloride, showing its molecular arrangement including the naphthyl, thiophene, and amine hydrochloride components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.